

## **INVO Bioscience to Report Third Quarter 2022 Financial Results on Monday, November 14, 2022**

*Financial results to be released after market close; Conference call to be conducted at 4:30 pm ET*

SARASOTA, Fla., Nov. 10, 2022 — **INVO Bioscience, Inc. (NASDAQ: INVO)**, a commercial-stage fertility company focused on expanding access to advanced treatment worldwide with its INVOcell® medical device and the IVC procedure it enables, will report financial results for its third quarter 2022, ended September 30, 2022, after the market close on Monday, November 14, 2022. The Company has scheduled a conference call that same day, Monday, November 14, 2022, at 4:30 pm ET, to review the results.



### **Third Quarter 2022 Conference Call Details**

**Date and Time:** Monday, November 14, 2022 at 4:30 pm ET

**Call-in Information:** Interested parties can access the conference call by dialing 833-756-0861 or 412-317-5751.

**Live Webcast Information:** Interested parties can access the conference call via a live webcast, which is available in the Investor Relations section of the Company's website at <https://www.invobioscience.com/investors/> or <https://app.webinar.net/054qIPLIQ9N>.

**Replay:** A teleconference replay of the call will be available through November 21, 2022, at 877-344-7529 or 412-317-0088, replay access code #3578858. A webcast replay will be available in the Investor Relations section of the Company's website at <https://www.invobioscience.com/investors/> for 90 days.

### **About INVO Bioscience**

We are a medical device company focused on creating simplified, lower-cost treatments for patients diagnosed with infertility. Our solution, the INVO® Procedure, is a revolutionary in vivo method of vaginal incubation that offers patients a more natural and intimate experience. Our lead product, the INVOcell®, is a patented medical device used in infertility treatment and is considered an Assisted Reproductive Technology (ART). The INVOcell® is the

first Intravaginal Culture (IVC) system in the world used for the natural in vivo incubation of eggs and sperm during fertilization and early embryo development, as an alternative to traditional In Vitro Fertilization (IVF) and Intrauterine Insemination (IUI). Our mission is to increase access to care and expand fertility treatment across the globe with a goal to lower the cost of care and increase the availability of care. For more information, please visit <http://invobioscience.com/>

### **Safe Harbor Statement**

This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The Company invokes the protections of the Private Securities Litigation Reform Act of 1995. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategies, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include words such as “anticipate,” “if,” “believe,” “plan,” “estimate,” “expect,” “intend,” “may,” “could,” “should,” “will,” and other similar expressions are forward-looking statements. All forward-looking statements involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. Factors that may cause actual results to differ materially from those in the forward-looking statements include those set forth in our filings at [www.sec.gov](http://www.sec.gov). We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events or otherwise.

 View original content to download

multimedia:<https://www.prnewswire.com/news-releases/invo-bioscience-to-report-third-quarter-2022-financial-results-on-monday-november-14-2022-301674776.html>

SOURCE INVO Bioscience, Inc.